Plain-English translation of NCT07014449 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called WBC100 to see if it is safe and effective for people with acute myeloid leukemia (a serious blood cancer) that has either returned after treatment or stopped responding to standard therapies. The study will enroll about 18 patients and test different doses of the medication to find the safest and most effective dose. Researchers will monitor your health closely with blood tests and regular check-ins to see how well the treatment works and what side effects you might experience.
Acute myeloid leukemia can be very difficult to treat when it comes back or becomes resistant to standard chemotherapy. This trial is exploring whether this new treatment could offer hope to patients who have limited options and need new approaches to fight their disease.
You likely qualify if…
You likely don't qualify if…
You would take a capsule of the medication by mouth once daily in 28-day treatment cycles. During the trial, you'll have regular blood tests and visits to check your safety and how well the treatment is working—researchers will watch closely for any side effects and adjust your dose if needed. Treatment continues until your cancer responds, your condition gets worse, you experience unacceptable side effects, or you decide to stop.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China